Global Small Molecule Chemical Drug CDMO 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI06251684

Publication Date:

June 27, 2025

Pages:

150

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Small Molecule Chemical Drug CDMO market size is predicted to grow from US$ 62690 million in 2025 to US$ 126740 million in 2031; it is expected to grow at a CAGR of 12.4% from 2025 to 2031.
The development and production of small molecule chemical drugs usually involves many complex steps, and the synthesis and production of small molecule chemical drugs require specialized equipment and technology. CDMO (Contract Development and Manufacturing Organization) is an organization that provides outsourcing services to pharmaceutical companies. It can provide a range of services from drug development to production.
United States market for Small Molecule Chemical Drug CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Small Molecule Chemical Drug CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Small Molecule Chemical Drug CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Small Molecule Chemical Drug CDMO players cover Haixiang Pharmaceutical, Innovent Biologics, Betta Pharmaceuticals, Jiuzhou Pharmaceutical, Puluo Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淪mall Molecule Chemical Drug CDMO Industry Forecast鈥� looks at past sales and reviews total world Small Molecule Chemical Drug CDMO sales in 2024, providing a comprehensive analysis by region and market sector of projected Small Molecule Chemical Drug CDMO sales for 2025 through 2031. With Small Molecule Chemical Drug CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Small Molecule Chemical Drug CDMO industry.
This Insight Report provides a comprehensive analysis of the global Small Molecule Chemical Drug CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Small Molecule Chemical Drug CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Small Molecule Chemical Drug CDMO market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Small Molecule Chemical Drug CDMO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Small Molecule Chemical Drug CDMO.
This report presents a comprehensive overview, market shares, and growth opportunities of Small Molecule Chemical Drug CDMO market by product type, application, key players and key regions and countries.
Segmentation by Type:
Human Medicine
Veterinary Medicine
Segmentation by Application:
Clinical Stage Projects
Commercialization Stage Projects
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Haixiang Pharmaceutical
Innovent Biologics
Betta Pharmaceuticals
Jiuzhou Pharmaceutical
Puluo Pharmaceutical
Menohua
Tianyu shares
Aoxiang Pharmaceutical
Hetero
CellMark
R&D Systems
Porton Pharmaceuticals
Kai Laiying
Smart Life
Notai Biotech
Aurobindo Pharma
Lonza Group
Catalent Inc.
Recipharm AB
Jubilant Pharmova Ltd
Patheon Inc. (Thermo Fisher Scientific Inc.)
Boehringer Ingelheim Group
Pfizer CentreSource
Baxter International Inc.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Small Molecule Chemical Drug CDMO 麻豆原创 Size (2020-2031)
2.1.2 Small Molecule Chemical Drug CDMO 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Small Molecule Chemical Drug CDMO by Country/Region (2020, 2024 & 2031)
2.2 Small Molecule Chemical Drug CDMO Segment by Type
2.2.1 Human Medicine
2.2.2 Veterinary Medicine
2.3 Small Molecule Chemical Drug CDMO 麻豆原创 Size by Type
2.3.1 Small Molecule Chemical Drug CDMO 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Small Molecule Chemical Drug CDMO 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Small Molecule Chemical Drug CDMO Segment by Application
2.4.1 Clinical Stage Projects
2.4.2 Commercialization Stage Projects
2.5 Small Molecule Chemical Drug CDMO 麻豆原创 Size by Application
2.5.1 Small Molecule Chemical Drug CDMO 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Small Molecule Chemical Drug CDMO 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Small Molecule Chemical Drug CDMO 麻豆原创 Size by Player
3.1 Small Molecule Chemical Drug CDMO 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Small Molecule Chemical Drug CDMO Revenue by Player (2020-2025)
3.1.2 Global Small Molecule Chemical Drug CDMO Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Small Molecule Chemical Drug CDMO Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Small Molecule Chemical Drug CDMO by Region
4.1 Small Molecule Chemical Drug CDMO 麻豆原创 Size by Region (2020-2025)
4.2 Global Small Molecule Chemical Drug CDMO Annual Revenue by Country/Region (2020-2025)
4.3 Americas Small Molecule Chemical Drug CDMO 麻豆原创 Size Growth (2020-2025)
4.4 APAC Small Molecule Chemical Drug CDMO 麻豆原创 Size Growth (2020-2025)
4.5 Europe Small Molecule Chemical Drug CDMO 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Small Molecule Chemical Drug CDMO 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Small Molecule Chemical Drug CDMO 麻豆原创 Size by Country (2020-2025)
5.2 Americas Small Molecule Chemical Drug CDMO 麻豆原创 Size by Type (2020-2025)
5.3 Americas Small Molecule Chemical Drug CDMO 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Small Molecule Chemical Drug CDMO 麻豆原创 Size by Region (2020-2025)
6.2 APAC Small Molecule Chemical Drug CDMO 麻豆原创 Size by Type (2020-2025)
6.3 APAC Small Molecule Chemical Drug CDMO 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Small Molecule Chemical Drug CDMO 麻豆原创 Size by Country (2020-2025)
7.2 Europe Small Molecule Chemical Drug CDMO 麻豆原创 Size by Type (2020-2025)
7.3 Europe Small Molecule Chemical Drug CDMO 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Small Molecule Chemical Drug CDMO by Region (2020-2025)
8.2 Middle East & Africa Small Molecule Chemical Drug CDMO 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Small Molecule Chemical Drug CDMO 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Small Molecule Chemical Drug CDMO 麻豆原创 Forecast
10.1 Global Small Molecule Chemical Drug CDMO Forecast by Region (2026-2031)
10.1.1 Global Small Molecule Chemical Drug CDMO Forecast by Region (2026-2031)
10.1.2 Americas Small Molecule Chemical Drug CDMO Forecast
10.1.3 APAC Small Molecule Chemical Drug CDMO Forecast
10.1.4 Europe Small Molecule Chemical Drug CDMO Forecast
10.1.5 Middle East & Africa Small Molecule Chemical Drug CDMO Forecast
10.2 Americas Small Molecule Chemical Drug CDMO Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Small Molecule Chemical Drug CDMO Forecast
10.2.2 Canada 麻豆原创 Small Molecule Chemical Drug CDMO Forecast
10.2.3 Mexico 麻豆原创 Small Molecule Chemical Drug CDMO Forecast
10.2.4 Brazil 麻豆原创 Small Molecule Chemical Drug CDMO Forecast
10.3 APAC Small Molecule Chemical Drug CDMO Forecast by Region (2026-2031)
10.3.1 China Small Molecule Chemical Drug CDMO 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Small Molecule Chemical Drug CDMO Forecast
10.3.3 Korea 麻豆原创 Small Molecule Chemical Drug CDMO Forecast
10.3.4 Southeast Asia 麻豆原创 Small Molecule Chemical Drug CDMO Forecast
10.3.5 India 麻豆原创 Small Molecule Chemical Drug CDMO Forecast
10.3.6 Australia 麻豆原创 Small Molecule Chemical Drug CDMO Forecast
10.4 Europe Small Molecule Chemical Drug CDMO Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Small Molecule Chemical Drug CDMO Forecast
10.4.2 France 麻豆原创 Small Molecule Chemical Drug CDMO Forecast
10.4.3 UK 麻豆原创 Small Molecule Chemical Drug CDMO Forecast
10.4.4 Italy 麻豆原创 Small Molecule Chemical Drug CDMO Forecast
10.4.5 Russia 麻豆原创 Small Molecule Chemical Drug CDMO Forecast
10.5 Middle East & Africa Small Molecule Chemical Drug CDMO Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Small Molecule Chemical Drug CDMO Forecast
10.5.2 South Africa 麻豆原创 Small Molecule Chemical Drug CDMO Forecast
10.5.3 Israel 麻豆原创 Small Molecule Chemical Drug CDMO Forecast
10.5.4 Turkey 麻豆原创 Small Molecule Chemical Drug CDMO Forecast
10.6 Global Small Molecule Chemical Drug CDMO Forecast by Type (2026-2031)
10.7 Global Small Molecule Chemical Drug CDMO Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Small Molecule Chemical Drug CDMO Forecast
11 Key Players Analysis
11.1 Haixiang Pharmaceutical
11.1.1 Haixiang Pharmaceutical Company Information
11.1.2 Haixiang Pharmaceutical Small Molecule Chemical Drug CDMO Product Offered
11.1.3 Haixiang Pharmaceutical Small Molecule Chemical Drug CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Haixiang Pharmaceutical Main Business Overview
11.1.5 Haixiang Pharmaceutical Latest Developments
11.2 Innovent Biologics
11.2.1 Innovent Biologics Company Information
11.2.2 Innovent Biologics Small Molecule Chemical Drug CDMO Product Offered
11.2.3 Innovent Biologics Small Molecule Chemical Drug CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Innovent Biologics Main Business Overview
11.2.5 Innovent Biologics Latest Developments
11.3 Betta Pharmaceuticals
11.3.1 Betta Pharmaceuticals Company Information
11.3.2 Betta Pharmaceuticals Small Molecule Chemical Drug CDMO Product Offered
11.3.3 Betta Pharmaceuticals Small Molecule Chemical Drug CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Betta Pharmaceuticals Main Business Overview
11.3.5 Betta Pharmaceuticals Latest Developments
11.4 Jiuzhou Pharmaceutical
11.4.1 Jiuzhou Pharmaceutical Company Information
11.4.2 Jiuzhou Pharmaceutical Small Molecule Chemical Drug CDMO Product Offered
11.4.3 Jiuzhou Pharmaceutical Small Molecule Chemical Drug CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 Jiuzhou Pharmaceutical Main Business Overview
11.4.5 Jiuzhou Pharmaceutical Latest Developments
11.5 Puluo Pharmaceutical
11.5.1 Puluo Pharmaceutical Company Information
11.5.2 Puluo Pharmaceutical Small Molecule Chemical Drug CDMO Product Offered
11.5.3 Puluo Pharmaceutical Small Molecule Chemical Drug CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Puluo Pharmaceutical Main Business Overview
11.5.5 Puluo Pharmaceutical Latest Developments
11.6 Menohua
11.6.1 Menohua Company Information
11.6.2 Menohua Small Molecule Chemical Drug CDMO Product Offered
11.6.3 Menohua Small Molecule Chemical Drug CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Menohua Main Business Overview
11.6.5 Menohua Latest Developments
11.7 Tianyu shares
11.7.1 Tianyu shares Company Information
11.7.2 Tianyu shares Small Molecule Chemical Drug CDMO Product Offered
11.7.3 Tianyu shares Small Molecule Chemical Drug CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 Tianyu shares Main Business Overview
11.7.5 Tianyu shares Latest Developments
11.8 Aoxiang Pharmaceutical
11.8.1 Aoxiang Pharmaceutical Company Information
11.8.2 Aoxiang Pharmaceutical Small Molecule Chemical Drug CDMO Product Offered
11.8.3 Aoxiang Pharmaceutical Small Molecule Chemical Drug CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 Aoxiang Pharmaceutical Main Business Overview
11.8.5 Aoxiang Pharmaceutical Latest Developments
11.9 Hetero
11.9.1 Hetero Company Information
11.9.2 Hetero Small Molecule Chemical Drug CDMO Product Offered
11.9.3 Hetero Small Molecule Chemical Drug CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Hetero Main Business Overview
11.9.5 Hetero Latest Developments
11.10 CellMark
11.10.1 CellMark Company Information
11.10.2 CellMark Small Molecule Chemical Drug CDMO Product Offered
11.10.3 CellMark Small Molecule Chemical Drug CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 CellMark Main Business Overview
11.10.5 CellMark Latest Developments
11.11 R&D Systems
11.11.1 R&D Systems Company Information
11.11.2 R&D Systems Small Molecule Chemical Drug CDMO Product Offered
11.11.3 R&D Systems Small Molecule Chemical Drug CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 R&D Systems Main Business Overview
11.11.5 R&D Systems Latest Developments
11.12 Porton Pharmaceuticals
11.12.1 Porton Pharmaceuticals Company Information
11.12.2 Porton Pharmaceuticals Small Molecule Chemical Drug CDMO Product Offered
11.12.3 Porton Pharmaceuticals Small Molecule Chemical Drug CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.12.4 Porton Pharmaceuticals Main Business Overview
11.12.5 Porton Pharmaceuticals Latest Developments
11.13 Kai Laiying
11.13.1 Kai Laiying Company Information
11.13.2 Kai Laiying Small Molecule Chemical Drug CDMO Product Offered
11.13.3 Kai Laiying Small Molecule Chemical Drug CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.13.4 Kai Laiying Main Business Overview
11.13.5 Kai Laiying Latest Developments
11.14 Smart Life
11.14.1 Smart Life Company Information
11.14.2 Smart Life Small Molecule Chemical Drug CDMO Product Offered
11.14.3 Smart Life Small Molecule Chemical Drug CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.14.4 Smart Life Main Business Overview
11.14.5 Smart Life Latest Developments
11.15 Notai Biotech
11.15.1 Notai Biotech Company Information
11.15.2 Notai Biotech Small Molecule Chemical Drug CDMO Product Offered
11.15.3 Notai Biotech Small Molecule Chemical Drug CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.15.4 Notai Biotech Main Business Overview
11.15.5 Notai Biotech Latest Developments
11.16 Aurobindo Pharma
11.16.1 Aurobindo Pharma Company Information
11.16.2 Aurobindo Pharma Small Molecule Chemical Drug CDMO Product Offered
11.16.3 Aurobindo Pharma Small Molecule Chemical Drug CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.16.4 Aurobindo Pharma Main Business Overview
11.16.5 Aurobindo Pharma Latest Developments
11.17 Lonza Group
11.17.1 Lonza Group Company Information
11.17.2 Lonza Group Small Molecule Chemical Drug CDMO Product Offered
11.17.3 Lonza Group Small Molecule Chemical Drug CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.17.4 Lonza Group Main Business Overview
11.17.5 Lonza Group Latest Developments
11.18 Catalent Inc.
11.18.1 Catalent Inc. Company Information
11.18.2 Catalent Inc. Small Molecule Chemical Drug CDMO Product Offered
11.18.3 Catalent Inc. Small Molecule Chemical Drug CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.18.4 Catalent Inc. Main Business Overview
11.18.5 Catalent Inc. Latest Developments
11.19 Recipharm AB
11.19.1 Recipharm AB Company Information
11.19.2 Recipharm AB Small Molecule Chemical Drug CDMO Product Offered
11.19.3 Recipharm AB Small Molecule Chemical Drug CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.19.4 Recipharm AB Main Business Overview
11.19.5 Recipharm AB Latest Developments
11.20 Jubilant Pharmova Ltd
11.20.1 Jubilant Pharmova Ltd Company Information
11.20.2 Jubilant Pharmova Ltd Small Molecule Chemical Drug CDMO Product Offered
11.20.3 Jubilant Pharmova Ltd Small Molecule Chemical Drug CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.20.4 Jubilant Pharmova Ltd Main Business Overview
11.20.5 Jubilant Pharmova Ltd Latest Developments
11.21 Patheon Inc. (Thermo Fisher Scientific Inc.)
11.21.1 Patheon Inc. (Thermo Fisher Scientific Inc.) Company Information
11.21.2 Patheon Inc. (Thermo Fisher Scientific Inc.) Small Molecule Chemical Drug CDMO Product Offered
11.21.3 Patheon Inc. (Thermo Fisher Scientific Inc.) Small Molecule Chemical Drug CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.21.4 Patheon Inc. (Thermo Fisher Scientific Inc.) Main Business Overview
11.21.5 Patheon Inc. (Thermo Fisher Scientific Inc.) Latest Developments
11.22 Boehringer Ingelheim Group
11.22.1 Boehringer Ingelheim Group Company Information
11.22.2 Boehringer Ingelheim Group Small Molecule Chemical Drug CDMO Product Offered
11.22.3 Boehringer Ingelheim Group Small Molecule Chemical Drug CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.22.4 Boehringer Ingelheim Group Main Business Overview
11.22.5 Boehringer Ingelheim Group Latest Developments
11.23 Pfizer CentreSource
11.23.1 Pfizer CentreSource Company Information
11.23.2 Pfizer CentreSource Small Molecule Chemical Drug CDMO Product Offered
11.23.3 Pfizer CentreSource Small Molecule Chemical Drug CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.23.4 Pfizer CentreSource Main Business Overview
11.23.5 Pfizer CentreSource Latest Developments
11.24 Baxter International Inc.
11.24.1 Baxter International Inc. Company Information
11.24.2 Baxter International Inc. Small Molecule Chemical Drug CDMO Product Offered
11.24.3 Baxter International Inc. Small Molecule Chemical Drug CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.24.4 Baxter International Inc. Main Business Overview
11.24.5 Baxter International Inc. Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.